DMPA Use for Complex Hyperplasia Without Atypia

Recommended Treatment Approach

The American College of Obstetricians and Gynecologists recommends oral progestins, such as medroxyprogesterone acetate 400-600 mg/day or megestrol acetate 160-320 mg/day, as the standard treatment for complex hyperplasia without atypia 1
The American College of Obstetricians and Gynecologists suggests that the levonorgestrel-releasing intrauterine system is increasingly preferred as initial therapy, delivering high local progesterone concentrations directly to the endometrium and demonstrating higher regression rates, lower recurrence rates, and fewer systemic adverse effects compared to oral progestins 1

Hysterectomy is not the preferred initial treatment for complex hyperplasia without atypia, but should be considered in cases of failure to respond to medical therapy after 6-12 months, recurrent disease after initial regression, or patient preference when fertility is not desired 1
The American College of Obstetricians and Gynecologists recommends reserving surgical management for patients who are unable to tolerate or comply with medical therapy and monitoring 1

The American College of Obstetricians and Gynecologists advises against confusing DMPA injectable contraception with oral medroxyprogesterone acetate therapy, as the dosing, pharmacokinetics, and endometrial effects are completely different, with therapeutic oral MPA requiring 400-600 mg daily for hyperplasia treatment 1
The American College of Obstetricians and Gynecologists recommends ensuring a specialist gynaecopathologist confirms the diagnosis of complex hyperplasia without atypia before initiating medical therapy, as misclassification could lead to undertreatment of atypical hyperplasia or occult carcinoma 1
The American College of Obstetricians and Gynecologists suggests counseling patients about the need for long-term surveillance, as recurrence rates can reach 30-40% with some treatment regimens 1